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We aimed to compare the anti-inflammatory activities of six species of Curcuma drugs using adjuvant
arthritis model mice. When orally administered 1 day before the injection of adjuvant, the methanol
extract of Curcuma phaeocaulis significantly inhibited paw swelling and the serum haptoglobin
concentration in adjuvant arthritis mice. Also when orally administered 1 day after the injection of
adjuvant, the methanol extract of Curcuma phaeocaulis significantly inhibited paw swelling. Other
Curcuma species (Curcuma longa, Curcuma wenyujin, Curcuma kwangsiensis, Curcuma zedoaria
and Curcuma aromatica) had no significant inhibitory effects on adjuvant-induced paw swelling.
Cyclooxygenase (COX)-2 activity was significantly inhibited by the methanol extract of C. phaeocaulis.
Curcuminoids’ (curcumin, bis-demethoxycurcumin and demethoxycurcumin) were rich in C. longa, but
less in C. phaeocaulis and C. aromatica, not in C. wenyujin, C. kwangsiensis and C. zedoaria, suggesting
that curcuminoids’ contents do not relate to inhibition of arthritis swelling. Therefore, C. phaeocaulis
may be a useful drug among Curcuma species for acute inflammation, and the active constituents of
C. phaeocaulis are not curcuminoids.
Keywords: adjuvant – arthritis – COX-2 – Curcuma – haptoglobin
Introduction
Many reports have suggested useful pharmacological
properties of Curcuma drugs such as anti-inflammatory (1),
anti-tumor (2) and immunological effects (3). Traditionally,
Curcuma drugs called ‘Ukon’ and ‘Gajutsu’ in Japanese have
been used in Oketsu syndromes (caused by the obstruction of
blood circulation) in Chinese medicine (4). Since the pharma-
cological effects of curcuminoids, especially curcumin, have
been investigated, such as radical scavenging (5), the inhibi-
tion of nitric oxide (NO) (6,7), anti-inflammation (8),
anti-tumor (9), anti-allergy (10) and anti-dementia (11), the
usefulness of ‘Ukon’ derived from Curcuma longa has been
intensively studied. Pharmacological studies of other Curcuma
species were very few, because botanical origins of Curcuma
drugs could not be easily identified due to similarity of mor-
phology, and variety of naming derived from used parts and
producing areas. At present, four Curcuma drugs are pre-
scribed in Chinese Pharmacopoeia; Yujin (the tubers of
Curcuma wenyujin, C. longa, Curcuma kwangsiensis or
Curcuma phaeocaulis); Jianghuang (the rhizome of C. longa);
Pian-Jianghuang (the rhizome of C. wenyujin) and Ezhu (the
rhizomes of C. phaeocaulis, C. kwangsiensis or C. wenyujin).
In addition, the rhizomes of Curcuma zedoaria and Curcuma
aromatica have been used in Japan as a medicine or supple-
ment. We previously compared five types of Curcuma drugs
(rhizomes of C. longa, C. kwangsiensis, C. phaeocaulis,
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by molecular biological analysis (12), on vasomotion in
isolated rat aortas, and we found that the methanol extracts
of all species had NO-independent relaxation effects (13). How-
ever, potencies of these vasomotion effects were not signifi-
cantly different between species. In this study, we focused on
evaluating differences among the anti-inflammatory activities
of six Curcuma drugs (C. longa, C. wenyujin, C. phaeocaulis,
C. kwangsiensis, C. zedaria and C. aromatica).
Materials and Methods
The six Curcuma drugs were used as shown in Table 1 and
Fig. 1, which were correctly identified by the molecular bio-
logical method previously reported (12). All drugs were stored
in the Museum of Materia Medica, Institute of Natural Medi-
cine, University of Toyama (TMPW), Japan.
Preparation of Extracts
Methanolextractswerepreparedasfollows:400gofpowdered
drug was placed in methanol (1 l · 2) for 12 h at room
temperature. The combined supernatants were evaporated on
a water bath to obtain the methanol extracts. The extracts
were dissolved in dimethyl sulfoxide (DMSO) (stock solution)
and then suspended in olive oil in animal experiments.
The extract was administered orally [500 mg kg
 1,
400 ml per mouse (olive oil : stock solution in DMSO ¼
320 ml:8 0ml)].
Induction of Arthritis
The mice were handled in accordance with the Guide for
Animal Experiments, University of Toyama. Arthritis was
induced in male ddY mice (6 week old; SLC, Shizuoka, Japan)
by injecting 50 mg per 50 ml
 1 of Complete Freund’s adjuvant
(CFA) (Sigma, St Louis, USA) into the right-hind footpad. The
vehicle injection was 50 ml paraffin oil. In Fig. 2, immediately
before and 1 day after injection of CFA, right footpad swelling
Table 1. Curcuma drugs used in this study and the yields of extracts
Herbal drug name Abbreviation Part used Cultivated area Yield (%) TMPW No.
a
Japanese Chinese Scientific name
Ukon Jianghuang Curcuma longa L. CL Rhizome Guangdong, China 14.0 22 295
b
14.8 19 910
c
Henkyouou Pian-Jianghuang C. wenyujin Y.H. Chen and C. Ling CW Rhizome Zhejiang, China 12.1 22 292
b
12.3 19 911
c
Gajutsu Ezhu C. phaeocaulis Val. CP Rhizome Sichuan, China 6.5 22 297
b
9.2 20 237
c
Gajutsu Ezhu C. kwangsiensis S.G. Lee and C.F. Liang CK Rhizome Guangxi, China 2.0 22 471
b
1.9 19 912
c
Gajutsu — C. zedoaria Rosc CZ Rhizome Kagoshima, Okinawa, Japan 8.9 22 473
b
7.0 20 285
c
Haruukon — C. aromatica CA Rhizoma Okinawa, Japan 7.5 22 312
b
8.9 20 284
c
aThe number shows the registration number of the Museum of Materia Medica, Institute of Natural Medicine, University of Toyama (TMPW). These drugs were
identified by the molecular biological method previously reported (13).
bUsed in Figs 2–4.
cUsed in Table 2.
Figure 1. Morphologies of used Curcuma drugs.
256 Anti-inflammatory activities of six Curcuma drugs(length · wide) was measured with slide calipers. In Fig. 3,
immediately before, 1 day after and 2 day after the injection
of CFA, right footpad swelling (length · wide) was measured
with slide calipers. Extracts were administered once 1 day after
the adjuvant injection. The change rate of paw swelling was
calculated. The paw sizes did not change before and after
extract administration.
Measurement of Haptoglobin
After measuring the footpads, blood (1 ml) was collected from
the vena cava and added to a serum collection tube. After
centrifugation (3500 r.p.m., 20 min), the supernatant was trans-
ferred into a new tube as a serum sample (400 ml). The concen-
tration of haptoglobin in serum was measured using PHASE
RANGE (Tridelta Development Limited, Maynooth, Ireland).
Measurement of COX-1 and COX-2
Cyclooxygenase (COX) activity was measured using a Colori-
metric COX inhibitor assay kit (Cayman, Ann Arbor, USA).
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Figure 2. Effects of pretreatment with methanolextracts of Curcumadrugs on
paw swelling and increase in serum haptoglobin induced by adjuvant injection.
Extracts of Curcuma drugs (500 mg kg
 1, hatched columns), dexamethasone
(5 mg kg
 1) or were administered once 1 day before the adjuvant injection.
Arthritis was induced by the injection of Complete Freund’s adjuvant (CFA)
into the right-hind footpad. Paraffin oil was injected in control mice.
(A) Immediately before, and 1 day after injection of the adjuvant, swelling
of the right footpad was measured with slide calipers. Change rate of the swel-
ling of Day 2 compared with Day 1 was calculated. (B) After footpad measure-
ment, serum was collected. The concentration of haptoglobin in serum was
measured. The time schedule of treatments is shown in the bottom. The values
represent the means and SEM of 5 mice. *P < 0.05 when compared with Veh.
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Figure 3. Post-treatment with methanol extracts of Curcuma drugs and its
effect on paw swelling and increase in serum haptoglobin induced by adjuvant
injection. Extracts of Curcuma drugs (500 mg kg
 1), dexamethasone
(5 mg kg
 1) or 20% DMSO in olive oil (Veh) were administered once 1 day
after the adjuvant injection. Arthritis was induced by the injection of Complete
Freund’s adjuvant (CFA) into the right-hind footpad. Paraffin oil was injected
in control mice. (A) Immediately before, 1 day after and 2 days after injection
of the adjuvant, swelling of the right footpad was measured with slide calipers.
Change rates of the swelling of Day 1 (open columns) and Day 2 (hatched col-
umns) compared with Day 0 were calculated. (B) After footpad measurement,
serum was collected at Day 2. The concentration of haptoglobin in serum was
measured. The time schedule of treatments is shown in the bottom. The values
represent the means and SEM of five mice. *P < 0.05 when compared
between before and after extract treatment in (A); *P < 0.05 when compared
with Veh in (B).
eCAM 2006;3(2) 257The methanol extracts or indomethacin were dissolved in
DMSO and added to the enzyme reaction mixture.
Quantifying Curcuminoid Content of Curcuma Drugs
Standard curcumin, bis-demethoxycurcumin and demethoxy-
curcumin were isolated and identified as pure compounds by
spectra data in our laboratory (13). Each standard curcuminoid
(1 mg) was accurately weighed and dissolved in methanol at a
concentration of 0.2 mg ml
 1. To draw calibration curves, a
series of standard solutions were prepared from the stock solu-
tion and filtered through a 0.2 mm Millipore filter (Advantec,
Tokyo, Japan). Dried Curcuma drugs were pulverized and
powdered. Methanol extracts of 20 mg were accurately
weighed and dissolved in methanol at a concentration of
0.4 mg ml
 1. After ultrasonication for 30 min, supernatants
were obtained by centrifugation at 2500 r.p.m. for 10 min.
The supernatants were transferred into volumetric flasks, and
methanol was added to obtain a final volume of 100 ml. After
filtration through a 0.2 mm Milllipore filter (Advantec), 5 ml
was injected into the HPLC system for analysis. The JASCO
HPLC system (Jasco, Tokyo, Japan) is composed of a PU-
1580 intelligent HPLC pump, a DG-1580-53 3-line degasser,
a LG-1580-02 ternary gradient unit, a CO-1565 intelligent col-
umn oven, an AS-2057 plus intelligent sampler and an MD-
1510 diode array detector. Comparative analysis was carried
out using a Mightysil RP-18GP (15 mm, 250 mm · 4.6 mm
i.d.) with a column temperature of 40 C. The mobile phase
was acetonitrile:water:acetic acid ¼ 45 : 55 : 1. The flow
rate was 1.0 ml min
 1 and the detection wavelength was
410 nm. The chromatographic data were collected and
processed using BORWIN-PDA APPLICATION and
BORWIN CHROMATOGRAPHY Software (version 1.5,
Jasco). The values of retention time of curcumin, bis-
demethoxycurcumin and demethoxycurcumin were 15.44,
11.75 and 13.48 min, respectively. The standard curves of
curcuminoids were made using a dose of 2–100 mgm l
 1.
Statistical Analysis
Statistical comparisons were carried out using one-way anal-
ysis of variance followed by Dunnett’s post hoc test or paired
t-test. Values of P < 0.05 were considered significant. The
means of the data are presented together with the SEM.
Results
We previously investigated the time-course of the paw edema
and confirmed that swelling peaked at 24 h post-injection
under our experimental conditions. In Fig. 2, methanol extracts
(500 mg kg
 1) were orally administered 1 day before the
adjuvant injection. Treatment with the C. phaeocaulis (CP)
extract significantly reduced the paw edema (Fig. 2A).
Although treatments with extracts of C. longa (CL),
C. kwangsiensis (CK) and C. zedoaria (CZ) tended to reduce
slightly the paw swelling, treatment with C. wenyujin (CW)
and C. aromatica (CA) did not. A steroidal anti-
inflammatory drug, dexamethasone, was used as a reference.
At a dose of 5 mg kg
 1, dexamethasone significantly inhibited
paw swelling. Although indomethacin (5 and 10 mg kg
 1),
a non-steroidal anti-inflammatory drug, was also used in this
experiment, several mice died after severe body weight loss.
Extract-treated groups showed no adverse effects. After
measuring the paw swelling, serum haptoglobin was detected
as an acute inflammation marker (14). The concentration of
serum haptoglobin intensively increased (10-fold the control)
by adjuvant injection (Fig. 2B). Serum haptoglobin was
significantly reduced in a CP extract-treated group (inhibition
rate: 72.5%) and CK extract-treated one (inhibition rate:
59.9%); however, no significant reduction was seen in other
Curcuma drug extract-treated groups. Dexamethasone (5 mg
kg
 1) did not reduce serum haptoglobin.
Paw Edema Significantly Reduced by C. phaeocaulis
In Fig. 3, methanol extracts (500 mg kg
 1) were orally admin-
istered 1 day after the adjuvant injection. Treatment with the
C. phaeocaulis (CP) extract significantly reduced paw edema
(Fig. 3A). Although treatments with extracts of CL, CW, CK,
CZ and CA tended to reduce the paw swelling, these were
not significant. Dexamethasone (5 mg kg
 1) significantly
inhibited paw swelling. Serum haptoglobin was slightly
reduced in CP and CK extracts-treated groups, but not signifi-
cantly. Dexamethasone (5 mg kg
 1) also did not reduce serum
haptoglobin significantly either.
Curcuma Extracts Showed Inhibitory Activity on
Enzymatic Activities In Vitro
The inhibitory effects of Curcuma extracts on in vitro enzym-
atic activities were measured against COX-2 and COX-1
(Fig. 4). The methanol extract of CP (500 mg/ml) significantly
inhibited COX-2 activity (inhibition rate: 24.4%). However,
CL, CW, CK, CZ and CA extracts demonstrated no signifi-
cant inhibition. For COX-1, CP, CL and CZ extracts
showed inhibitory activity, and the inhibition rate with the
CP extract was the most remarkable (inhibition rate: 38.4%).
Indomethacin, a COX inhibitor, inhibited COX-2 (inhibition
rate: 45.5% inhibition at 100 mM) and COX-1 (inhibition
rate: 37.2% at 100 mM) activities dose dependently. The
inhibitory efficacy of COX-2 with the methanol extract of
CP was weaker than that of 100 mM indomethacin.
Testing of Curcuma Samples from China and Japan
Confirmed That Curcumin was Rich in CL
The content of three curcuminoids in the methanol extracts of
Curcuma drugs was quantified as shown in (Table 2). In CP
and CA, a very small amount of curcumin was contained in
the methanol extract, in addition to bis-demethoxycurcumin
and demethoxycurcumin were hardly detected. None of the
three curcumnoids was present in CW, CK and CZ, whereas
large amounts of curcuminoids were detected in CL. In
particular, curcumin concentrations were high in the CL
258 Anti-inflammatory activities of six Curcuma drugsmethanol extract. We tested many Curcuma samples from
China and Japan, and confirmed that curcumin was rich in
CL (3.9–12.3% in the methanol extract), but not in CP, CW,
CK, CZ and CA.
Discussion
The methanol extract of CP significantly reduced paw swelling
(Fig. 2A) and the expression of an inflammation marker, hap-
toglobin in serum (Fig. 2B), of mice when it was administered
orally 1 day before the adjuvant injection. Also in case of treat-
ment with the methanol extracts 1 day after the adjuvant injec-
tion when the paw was maximally swollen, CP significantly
reduced paw swelling (Fig. 3A). However, treatment with the
methanol extracts of CL, CW, CZ and CA had no clear effects
on inflammation. Therefore, CP is to be expected the most
effective in reducing arthritis swelling among Curcuma drugs.
The methanol extract of CP had inhibitory activity on
inflammation-related enzymes, COX-2 (Fig. 4A). A selective
COX-2 inhibitor, SC-58125, rapidly reverses paw edema, the
level of PGE2, the expression of COX-2, and serum IL-6 and
paw IL-6 levels in arthritis rats induced by CFA (15). Upregu-
lated COX-2 also enhances PG production, and inflammation
progresses further (15). Therefore, the inhibitory effect of CP
on COX-2 activity may be useful to prevent inflammation.
Both CP and indomethacin were not selective inhibitors of
COX-2 (Fig. 4). Some indomethacin-treated mice died (data
not shown). It is known that indomethacin treatment has a
high risk of several adverse effects (gastrointestinal, hepatic
and kidney disorders), which may be caused mainly by the
inhibitory effect of COX-1. Considering that CP had anti-
inflammatory effects on arthritic mice (Figs 1 and 2) with no
adverse effects in spite of its COX-1 inhibitory action; some
constituents which relieve the adverse effects may be con-
tained in the methanol extract of CP. Dexamethasone did not
inhibittheserumhaptoglobinconcentration(Figs1and2).Each
class of anti-inflammatory drugs has a specific effect on the
regulation of acute phase proteins (16), and dexamethasone
is known not to reduce the haptoglobin expression (17).
In an arthritis animal model, IL-1b (18) and TNF-a (15) are
increased by inflammatory stimulation, and IL-1b induces
COX-2 transcription in inflammatory cells (19). At the same
time, increased IL-1b and TNF-a in inflammation upregulate
the IL-6 expression (20), and IL-6 stimulation in the liver
induces the translocation of activated STAT3 molecules to
nuclei (21,22). Transcription of the haptoglobin gene is
enhanced through multiple IL-6 response elements, and hap-
toglobin increases in the liver and serum (23). Since the
methanol extract of CP reduced serum haptoglobin in arthritis,
it may inhibit anywhere in the cytokine pathway. We will
investigate whether the expression levels of these cytokines
in serum, and the COX-2 level in paw tissue, are changed by
treatment with CP extract.
The pharmacological activities of curcumin have been
studied intensively from many viewpoints, suggesting that
curcumin inhibits LPS-induced NO production (5) and iNOS
expression (6), COX-2 expression and activation (24), and
expression of several inflammatory markers. In addition, cur-
cumin is cytotoxic in several cell types (25,26), not only in
cancer cells (27,28). Hepatotoxicity was reported in animal
experiments using curcumin-containing Curcuma drugs
(29,30), and although curcumin has many useful pharmaco-
logical and possible therapeutic activities, its safety should
be considered carefully. However, CP contains very low amounts
of curcuminoids (Table 2), but showed anti-inflammatory
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Figure 4. Inhibitory activities of methanol extracts of Curcuma drugs on
COX-2 and COX-1 activities. The methanol extracts of Curcuma drugs
(500 mgm l
 1, hatched columns), indomethacin (10 and 100 mM, closed col-
umns), or the vehicle (0.1% DMSO, open columns) were added to the enzyme
reaction mixture. COX-2 (A) and COX-1 (B) activities were measured using
the Colorimetric COX inhibitor assay kit. The values represented the means
and SEM. n ¼ 3. *P < 0.05 when compared with Veh.
Table 2. Curcuminoid contents in the methanol extracts
Contents (% in the methanol extract)
Curcumin Bisdemethoxy-
curcumin
Demethoxy-
curcumin
C. longa 12.30 4.86 3.62
C. wenyujin ND ND ND
C. phaeocaulis 0.89 ND t
C. kwangsiensis ND ND ND
C. zedoaria ND ND ND
C. aromatica 0.11 ND ND
ND, Not detected; t, trace.
eCAM 2006;3(2) 259activity (Figs 1 and 2), suggesting that some active con-
stituents other than curcuminoids may exist in CP. Since a
recent study showed that significant amounts of
furanodienone and curcumenol were contained in CP (31),
these compounds may be candidates for active principles. As
very little basic pharmacologicalresearchorchemicalanalyses
of CP have been performed, the usefulness of CP should be
investigated in future studies.
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